Dashboard
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate -248.87% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -0.60
Negative results in Jun 25
Risky - Negative EBITDA
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Specialty Chemicals
USD 143 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-1.63
28.37%
-0.49
Total Returns (Price + Dividend) 
Aemetis, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
Is Aemetis, Inc. technically bullish or bearish?
As of 10 September 2025, the technical trend for Aemetis, Inc. has changed from sideways to mildly bearish. The weekly MACD and KST indicators are both mildly bearish, while the monthly MACD is mildly bullish, indicating mixed signals across time frames. The daily moving averages are mildly bullish, but the overall sentiment is dampened by the weekly and monthly Dow Theory and OBV being mildly bearish. In terms of performance, Aemetis has underperformed the S&P 500 across multiple periods, with a year-to-date return of -10.04% compared to the S&P 500's 12.22%, and a three-year return of -68.85% versus the S&P 500's 70.41%. Overall, the current technical stance is mildly bearish....
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Domestic Funds
Held in 17 Schemes (13.79%)
Held by 31 Foreign Institutions (3.29%)
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
QoQ Growth in quarter ended Jun 2025 is 21.68% vs -8.72% in Mar 2025
QoQ Growth in quarter ended Jun 2025 is 4.49% vs -51.23% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is 43.33% vs -27.21% in Dec 2023
YoY Growth in year ended Dec 2024 is -88.58% vs 56.96% in Dec 2023






